

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application:

Claims 1-74 (cancelled).

Claim 75 (previously presented): A method of administering paclitaxel, comprising administering paclitaxel to a subject wherein the plasma level of paclitaxel in the subject is maintained at 0.01–0.05 µg/ml over a period of 7 days or more.

Claim 76 (previously presented): The method of claim 75, wherein the plasma level of paclitaxel in the subject is maintained at 0.01-0.05 µg/ml over a period of two weeks or more.

Claim 77 (previously presented): The method of claim 76, wherein the plasma level of paclitaxel in the subject is maintained at 0.01-0.05 µg/ml over a period of one month or more.

Claim 78 (previously presented): The method of claim 75, wherein the paclitaxel is administered systemically.

Claim 79 (previously presented): The method of claim 78, wherein the paclitaxel is administered orally.

Claim 80 (previously presented): The method of claim 78, wherein the paclitaxel is administered intravenously.

Claim 81 (previously presented): The method of claim 75, wherein the paclitaxel is administered locally.

Claim 82 (previously presented): The method of claim 81, wherein the paclitaxel is administered with slow release delivery vehicles.

Claim 83 (previously presented): The method of claim 75, wherein the paclitaxel is encapsulated in a colloidal dispersion system.

Claim 84 (previously presented): The method of claim 83, wherein the colloidal dispersion system comprises nanocapsules.

Claim 85 (previously presented): The method of claim 83, wherein the colloidal dispersion system comprises microspheres.

Claim 86 (previously presented): The method of claim 83, wherein the colloidal dispersion system comprises liposomes or oil-in-water emulsions.

Claim 87 (previously presented): The method of claim 75, wherein the paclitaxel is in polymer stabilized crystals.

Claim 88 (previously presented): The method of claim 75, wherein the paclitaxel is administered continuously.

Claim 89 (previously presented): The method of claim 75, wherein the subject is human.

Claim 90 (currently amended): A method of administering paclitaxel comprising administering paclitaxel to a subject over a period of 7 days or more, wherein the amount of paclitaxel is ~~about 1% to about 20%~~ of [[the]] ~~a~~ conventional dose of paclitaxel over the same period, and wherein a therapeutically effective plasma level of paclitaxel in the subject is maintained throughout the period of 7 days or more, wherein the conventional dose of paclitaxel is 135-175 mg/m² over a period of three weeks.

Claim 91 (previously presented): The method of claim 90, wherein the method comprises administering paclitaxel to a subject over a period of two weeks or more, and wherein a therapeutically effective plasma level of paclitaxel in the subject is maintained throughout the period of two weeks or more.

Claim 92 (previously presented): The method of claim 90, wherein the method comprises administering paclitaxel to a subject over a period of one month or more, and wherein a therapeutically effective plasma level of paclitaxel in the subject is maintained throughout the period of one month or more.

Claim 93 (currently amended): The method of claim 90, wherein the amount of paclitaxel is ~~about~~ 1% to ~~about~~ 10% of the conventional dose of paclitaxel over the same period.

Claim 94 (currently amended): The method of claim 93, wherein the amount of paclitaxel is ~~about~~ 1% to ~~about~~ 5% of the conventional dose of paclitaxel over the same period.

Claim 95 (previously presented): The method of claim 90, wherein the paclitaxel is administered systemically.

Claim 96 (previously presented): The method of claim 95, wherein the paclitaxel is administered orally.

Claim 97 (previously presented): The method of claim 95, wherein the paclitaxel is used intravenously.

Claim 98 (previously presented): The method of claim 90, wherein the paclitaxel is administered locally.

Claim 99 (previously presented): The method of claim 98, wherein the paclitaxel is administered with slow release delivery vehicles.

Claim 100 (previously presented): The method of claim 90, wherein the paclitaxel is encapsulated in a colloidal dispersion system.

Claim 101 (previously presented): The method of claim 100, wherein the colloidal dispersion system comprises nanocapsules.

Claim 102 (previously presented): The method of claim 100, wherein the colloidal dispersion system comprises microspheres.

Claim 103 (previously presented): The method of claim 100, wherein the colloidal dispersion system comprises liposomes or oil-in-water emulsions.

Claim 104 (previously presented): The method of claim 90, wherein the paclitaxel is in polymer stabilized crystals.

Claim 105 (cancelled).

Claim 106 (previously presented): The method of claim 90, wherein the paclitaxel is administered continuously.

Claim 107 (previously presented): The method of claim 90, wherein the paclitaxel is administered over a period of less than one year.

Claim 108 (previously presented): The method of claim 107, wherein the paclitaxel is administered over a period of less than three months.

Claim 109 (previously presented): The method of claim 108, wherein the paclitaxel is administered over a period of less than one month.

Claim 110 (previously presented): The method of claim 90, wherein the subject is human.

Claim 111 (currently amended): A method of administering paclitaxel comprising regularly administering paclitaxel to a subject over a period of 7 days or more to achieve a therapeutic benefit, wherein the amount of paclitaxel is ~~about 1% to about 10%~~ of [[the]] a conventional dose of paclitaxel over the same period, wherein the conventional dose of paclitaxel is 135-175 mg/m² over a period of three weeks.

Claim 112 (previously presented): The method of claim 111, wherein a therapeutically effective plasma level of paclitaxel is maintained throughout the period of 7 days or more.

Claim 113 (currently amended): The method of claim 111, wherein the amount of paclitaxel is about 1% to about 5% of the conventional dose of paclitaxel over the same period.

Claim 114 (previously presented): The method of claim 111, wherein the paclitaxel is administered systemically.

Claim 115 (previously presented): The method of claim 114, wherein the paclitaxel is administered orally.

Claim 116 (previously presented): The method of claim 114, wherein the paclitaxel is administered intravenously.

Claim 117 (previously presented): The method of claim 111, wherein the paclitaxel is administered locally.

Claim 118 (previously presented): The method of claim 117, wherein the paclitaxel is administered with slow release delivery vehicles.

Claim 119 (previously presented): The method of claim 111, wherein the paclitaxel is encapsulated in a colloidal dispersion system.

Claim 120 (previously presented): The method of claim 119, wherein the colloidal dispersion system comprises nanocapsules.

Claim 121 (previously presented): The method of claim 119, wherein the colloidal dispersion system comprises microspheres.

Claim 122 (previously presented): The method of claim 119, wherein the colloidal dispersion system comprises liposomes or oil-in-water emulsions.

Claim 123 (previously presented): The method of claim 111, wherein the paclitaxel is in polymer stabilized crystals.

Claim 124 (cancelled).

Claim 125 (previously presented): The method of claim 111, wherein the paclitaxel is administered continuously.

Claim 126 (previously presented): The method of claim 111, wherein the paclitaxel is administered over a period of less than one year.

Claim 127 (previously presented): The method of claim 126, wherein the paclitaxel is administered over a period of less than three months.

Claim 128 (previously presented): The method of claim 127, wherein the paclitaxel is administered over a period of less than one month.

Claim 129 (previously presented): The method of claim 111, wherein the subject is human.